{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T23:21:59Z","timestamp":1792279319506,"version":"4.4.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T00:00:00Z","timestamp":1672617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T00:00:00Z","timestamp":1672617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Biotechnol"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Monoclonal antibodies (Abs) that recognize major histocompatability complex (MHC)-presented tumor antigens in a manner similar to T\u2009cell receptors (TCRs) have great potential as cancer immunotherapeutics. However, isolation of \u2018TCR-mimic\u2019 (TCRm) Abs is laborious because Abs have not evolved the structurally nuanced peptide\u2013MHC restriction of \u03b1\u03b2-TCRs. Here, we present a strategy for rapid isolation of highly peptide-specific and \u2018MHC-restricted\u2019 Abs by re-engineering preselected Abs that engage peptide\u2013MHC in a manner structurally similar to that of conventional \u03b1\u03b2-TCRs. We created structure-based libraries focused on the peptide-interacting residues of TCRm Ab complementarity-determining region (CDR) loops, and rapidly generated MHC-restricted Abs to both mouse and human tumor antigens that specifically killed target cells when formatted as IgG, bispecific T cell engager (BiTE) and chimeric antigen receptor-T (CAR-T). Crystallographic analysis of one selected pMHC-restricted Ab revealed highly peptide-specific recognition, validating the engineering strategy. This approach can yield tumor antigen-specific antibodies in several weeks, potentially enabling rapid clinical translation.<\/jats:p>","DOI":"10.1038\/s41587-022-01567-w","type":"journal-article","created":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T12:02:56Z","timestamp":1672660976000},"page":"932-943","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Facile repurposing of peptide\u2013MHC-restricted antibodies for cancer immunotherapy"],"prefix":"10.1038","volume":"41","author":[{"given":"Xinbo","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Nishimiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"L\u00f6chte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin M.","family":"Jude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Borowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina S.","family":"Savvides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Dougan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7654-9997","authenticated-orcid":false,"given":"Leon","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2143-2270","authenticated-orcid":false,"given":"Jacob","family":"Piehler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9273-0278","authenticated-orcid":false,"given":"K. Christopher","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,2]]},"reference":[{"key":"1567_CR1","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/nrd3229","volume":"9","author":"AL Nelson","year":"2010","unstructured":"Nelson, A. L. et al. Development trends for human monoclonal antibody therapeutics. Nat. Rev. Drug Discov. 9, 767\u2013774 (2010).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1567_CR2","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrd.2016.268","volume":"16","author":"A Beck","year":"2017","unstructured":"Beck, A. et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat. Rev. Drug Discov. 16, 315\u2013337 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1567_CR3","doi-asserted-by":"publisher","first-page":"e1049803","DOI":"10.1080\/2162402X.2015.1049803","volume":"5","author":"L Dubrovsky","year":"2016","unstructured":"Dubrovsky, L. et al. T cell receptor mimic antibodies for cancer therapy. Oncoimmunology 5, e1049803 (2016).","journal-title":"Oncoimmunology"},{"key":"1567_CR4","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13045-019-0788-4","volume":"12","author":"Q He","year":"2019","unstructured":"He, Q. et al. TCR-like antibodies in cancer immunotherapy. J. Hematol. Oncol. 12, 99 (2019).","journal-title":"J. Hematol. Oncol."},{"key":"1567_CR5","doi-asserted-by":"publisher","first-page":"eabc8697","DOI":"10.1126\/science.abc8697","volume":"371","author":"EH Hsiue","year":"2021","unstructured":"Hsiue, E. H. et al. Targeting a neoantigen derived from a common TP53 mutation. Science 371, eabc8697 (2021).","journal-title":"Science"},{"key":"1567_CR6","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41586-021-04061-6","volume":"599","author":"M Yarmarkovich","year":"2021","unstructured":"Yarmarkovich, M. et al. Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs. Nature 599, 477\u2013484 (2021).","journal-title":"Nature"},{"key":"1567_CR7","doi-asserted-by":"publisher","first-page":"100745","DOI":"10.1016\/j.jbc.2021.100745","volume":"296","author":"IA Wilson","year":"2021","unstructured":"Wilson, I. A. & Stanfield, R. L. 50 Years of structural immunology. J. Biol. Chem. 296, 100745 (2021).","journal-title":"J. Biol. Chem."},{"key":"1567_CR8","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.cell.2005.07.015","volume":"122","author":"KC Garcia","year":"2005","unstructured":"Garcia, K. C. & Adams, E. J. How the T cell receptor sees antigen\u2014a structural view. Cell 122, 333\u2013336 (2005).","journal-title":"Cell"},{"key":"1567_CR9","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/ni.f.219","volume":"10","author":"KC Garcia","year":"2009","unstructured":"Garcia, K. C. et al. The molecular basis of TCR germline bias for MHC is surprisingly simple. Nat. Immunol. 10, 143\u2013147 (2009).","journal-title":"Nat. Immunol."},{"key":"1567_CR10","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/nature00920","volume":"418","author":"LC Wu","year":"2002","unstructured":"Wu, L. C. et al. The two-step binding mechanism for T-cell receptor recognition of peptide-MHC. Nature 418, 552\u2013556 (2002).","journal-title":"Nature"},{"key":"1567_CR11","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1080\/14712598.2016.1176138","volume":"16","author":"AY Chang","year":"2016","unstructured":"Chang, A. Y. et al. Opportunities and challenges for TCR mimic antibodies in cancer therapy. Expert Opin. Biol. Ther. 16, 979\u2013987 (2016).","journal-title":"Expert Opin. Biol. Ther."},{"key":"1567_CR12","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.3389\/fimmu.2017.01001","volume":"8","author":"I Trenevska","year":"2017","unstructured":"Trenevska, I. et al. Therapeutic antibodies against intracellular tumor antigens. Front. Immunol. 8, 1001 (2017).","journal-title":"Front. Immunol."},{"key":"1567_CR13","doi-asserted-by":"publisher","first-page":"176ra33","DOI":"10.1126\/scitranslmed.3005661","volume":"5","author":"T Dao","year":"2013","unstructured":"Dao, T. et al. Targeting the intracellular WT1 oncogene product with a therapeutic human antibody. Sci. Transl. Med. 5, 176ra33 (2013).","journal-title":"Sci. Transl. Med."},{"key":"1567_CR14","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1172\/JCI92335","volume":"127","author":"AY Chang","year":"2017","unstructured":"Chang, A. Y. et al. A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide\/HLA-I antigens. J. Clin. Invest. 127, 2705\u20132718 (2017).","journal-title":"J. Clin. Invest."},{"key":"1567_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13305-z","volume":"10","author":"L Low","year":"2019","unstructured":"Low, L. et al. Targeting mutant p53-expressing tumours with a T cell receptor-like antibody specific for a wild-type antigen. Nat. Commun. 10, 5382 (2019).","journal-title":"Nat. Commun."},{"key":"1567_CR16","first-page":"4187","volume":"37","author":"VP Wittman","year":"2007","unstructured":"Wittman, V. P. et al. Antibody targeting to a class I MHC-peptide epitope promotes tumor cell death. J. Immunol. 37, 4187\u20134195 (2007).","journal-title":"J. Immunol."},{"key":"1567_CR17","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.4049\/jimmunol.169.2.1110","volume":"169","author":"P Chames","year":"2002","unstructured":"Chames, P. et al. TCR-like human antibodies expressed on human CTLs mediate antibody affinity-dependent cytolytic activity. J. Immunol. 169, 1110\u20131118 (2002).","journal-title":"J. Immunol."},{"key":"1567_CR18","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1074\/jbc.M411323200","volume":"280","author":"M Hulsmeyer","year":"2005","unstructured":"Hulsmeyer, M. et al. A major histocompatibility complex peptide-restricted antibody and T cell receptor molecules recognize their target by distinct binding modes. J. Biol. Chem. 280, 2972\u20132980 (2005).","journal-title":"J. Biol. Chem."},{"key":"1567_CR19","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jmb.2015.12.002","volume":"428","author":"N Ataie","year":"2016","unstructured":"Ataie, N. et al. Structure of a TCR-mimic antibody with target predicts pharmacogenetics. J. Mol. Biol. 428, 194\u2013205 (2016).","journal-title":"J. Mol. Biol."},{"key":"1567_CR20","doi-asserted-by":"publisher","first-page":"29053","DOI":"10.1074\/jbc.M804996200","volume":"283","author":"T Mareeva","year":"2008","unstructured":"Mareeva, T. et al. How a T cell receptor-like antibody recognizes major histocompatibility complex-bound peptide. J. Biol. Chem. 283, 29053\u201329059 (2008).","journal-title":"J. Biol. Chem."},{"key":"1567_CR21","doi-asserted-by":"publisher","first-page":"5784","DOI":"10.1073\/pnas.0901425106","volume":"106","author":"G Stewart-Jones","year":"2009","unstructured":"Stewart-Jones, G. et al. Rational development of high-affinity T-cell receptor-like antibodies. Proc. Natl Acad. Sci. USA 106, 5784\u20135788 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1567_CR22","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1084\/jem.185.3.453","volume":"185","author":"MB Bloom","year":"1997","unstructured":"Bloom, M. B. et al. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J. Exp. Med. 185, 453\u2013459 (1997).","journal-title":"J. Exp. Med."},{"key":"1567_CR23","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.molimm.2014.09.017","volume":"63","author":"E Arduin","year":"2015","unstructured":"Arduin, E. et al. Highly reduced binding to high and low affinity mouse Fc gamma receptors by L234A\/L235A and N297A Fc mutation engineered into mouse IgG2a. Mol. Immunol. 63, 456\u2013463 (2015).","journal-title":"Mol. Immunol."},{"key":"1567_CR24","doi-asserted-by":"publisher","first-page":"4005","DOI":"10.1073\/pnas.0508123103","volume":"103","author":"GA Lazar","year":"2006","unstructured":"Lazar, G. A. et al. Engineered antibody Fc variants with enhanced effector function. Proc. Natl Acad. Sci. USA 103, 4005\u20134010 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1567_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12301-7","volume":"10","author":"H Gotzke","year":"2019","unstructured":"Gotzke, H. et al. The ALFA-tag is a highly versatile tool for nanobody-based bioscience applications. Nat. Commun. 10, 4403 (2019).","journal-title":"Nat. Commun."},{"key":"1567_CR26","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1038\/leu.2017.223","volume":"31","author":"MD Mathias","year":"2017","unstructured":"Mathias, M. D. et al. CD47 blockade enhances therapeutic activity of TCR mimic antibodies to ultra low density cancer epitopes. Leukemia. 31, 2254\u20132257 (2017).","journal-title":"Leukemia."},{"key":"1567_CR27","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/sj.gt.3301080","volume":"7","author":"KW Liao","year":"2000","unstructured":"Liao, K. W., Lo, Y. C. & Roffler, S. R. Activation of lymphocytes by anti-CD3 single-chain antibody dimers expressed on the plasma membrane of tumor cells. Gene Ther. 7, 339\u2013347 (2000).","journal-title":"Gene Ther."},{"key":"1567_CR28","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1084\/jem.187.2.265","volume":"187","author":"E Jager","year":"1998","unstructured":"Jager, E. et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J. Exp. Med. 187, 265\u2013270 (1998).","journal-title":"J. Exp. Med."},{"key":"1567_CR29","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1084\/jem.180.1.347","volume":"180","author":"Y Kawakami","year":"1994","unstructured":"Kawakami, Y. et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med. 180, 347\u2013352 (1994).","journal-title":"J. Exp. Med."},{"key":"1567_CR30","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/ijc.2910620118","volume":"62","author":"AB Bakker","year":"1995","unstructured":"Bakker, A. B. et al. Identification of a novel peptide derived from the melanocyte-specific gp100 antigen as the dominant epitope recognized by HLA-A2.1-restricted anti-melanoma CTL line. Int. J. Cancer 62, 97\u2013102 (1995).","journal-title":"Int. J. Cancer"},{"key":"1567_CR31","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1242\/jcs.182873","volume":"129","author":"GA Hobbs","year":"2016","unstructured":"Hobbs, G. A. et al. RAS isoforms and mutations in cancer at a glance. J. Cell Sci. 129, 1287\u20131292 (2016).","journal-title":"J. Cell Sci."},{"key":"1567_CR32","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.cell.2017.11.043","volume":"172","author":"MH Gee","year":"2018","unstructured":"Gee, M. H. et al. Antigen identification for orphan T cell receptors expressed on tumor-infiltrating lymphocytes. Cell 172, 549\u2013563 (2018).","journal-title":"Cell"},{"key":"1567_CR33","doi-asserted-by":"publisher","first-page":"4036","DOI":"10.1158\/1078-0432.CCR-13-2756","volume":"20","author":"N Veomett","year":"2014","unstructured":"Veomett, N. et al. Therapeutic efficacy of an Fc-enhanced TCR-like antibody to the intracellular WT1 oncoprotein. Clin. Cancer Res. 20, 4036\u20134046 (2014).","journal-title":"Clin. Cancer Res."},{"key":"1567_CR34","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1002\/eji.200737524","volume":"38","author":"M Epel","year":"2008","unstructured":"Epel, M. et al. Targeting TARP, a novel breast and prostate tumor-associated antigen, with T cell receptor-like human recombinant antibodies. Eur. J. Immunol. 38, 1706\u20131720 (2008).","journal-title":"Eur. J. Immunol."},{"key":"1567_CR35","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/nbt.3349","volume":"33","author":"T Dao","year":"2015","unstructured":"Dao, T. et al. Therapeutic bisepecific T-cell engager antibody targeting the intracellular oncoprotein WT1. Nat. Biotechnol. 33, 1079\u20131086 (2015).","journal-title":"Nat. Biotechnol."},{"key":"1567_CR36","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1017\/erm.2012.2","volume":"14","author":"R Dahan","year":"2012","unstructured":"Dahan, R. & Reiter, Y. T-cell-receptor-like antibodies-generation, function and applications. Expert Rev. Mol. Med. 14, e6 (2012).","journal-title":"Expert Rev. Mol. Med."},{"key":"1567_CR37","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2174\/1574884712666170809124728","volume":"13","author":"S Singh","year":"2018","unstructured":"Singh, S. et al. Monoclonal antibodies: a review. Curr. Clin. Pharmacol. 13, 85\u201399 (2018).","journal-title":"Curr. Clin. Pharmacol."},{"key":"1567_CR38","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1146\/annurev.immunol.23.021704.115658","volume":"24","author":"MG Rudolph","year":"2016","unstructured":"Rudolph, M. G. et al. How TCRs bind MHCs, peptide, and coreceptors. Annu. Rev. Immunol. 24, 419\u2013466 (2016).","journal-title":"Annu. Rev. Immunol."},{"key":"1567_CR39","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/978-1-59745-554-1_6","volume":"525","author":"Z Zhu","year":"2009","unstructured":"Zhu, Z. & Dimitrov, D. S. Construction of a large na\u00efve human phage-displayed Fab library through one-step cloning. Methods Mol. Biol. 525, 129\u2013142 (2009).","journal-title":"Methods Mol. Biol."},{"key":"1567_CR40","doi-asserted-by":"publisher","first-page":"3429","DOI":"10.1073\/pnas.89.8.3429","volume":"89","author":"DN Garboczi","year":"1992","unstructured":"Garboczi, D. N. et al. HLA-A2-peptide complexes: refolding and crystallization of molecules expressd in Escherichia coli and complexed with single antigenic peptides. Proc. Natl Acad. Sci. USA 89, 3429\u20133433 (1992).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1567_CR41","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1107\/S0907444910045749","volume":"67","author":"MD Winn","year":"2011","unstructured":"Winn, M. D. et al. Overview of the CCP4 suite and current developments. Acta Crystallogr. D Biol. Crystallogr. 67, 235\u2013242 (2011).","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"1567_CR42","unstructured":"Schr\u00f6dinger, L. & DeLano, W. PyMOL. http:\/\/www.pymol.org\/pymol (2020)."},{"key":"1567_CR43","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/nmeth.1233","volume":"5","author":"A Serge","year":"2008","unstructured":"Serge, A. et al. Dynamic multiple-target tracing to probe spatiotemporal cartography of cell membranes. Nat. Methods 5, 687\u2013694 (2008).","journal-title":"Nat. Methods"},{"key":"1567_CR44","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1023\/A:1009745219419","volume":"2","author":"J Sander","year":"1998","unstructured":"Sander, J. et al. Density-based clustering in spatial databases: the algorithm GDBSCAN and its applications. Data Min. Knowl. Discov. 2, 169\u2013194 (1998).","journal-title":"Data Min. Knowl. Discov."},{"key":"1567_CR45","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1083\/jcb.201709007","volume":"217","author":"B Niewidok","year":"2018","unstructured":"Niewidok, B. et al. Single-molecule imaging reveals dynamic biphasic partition of RNA-binding proteins in stress granules. J. Cell Biol. 217, 1303\u20131318 (2018).","journal-title":"J. Cell Biol."},{"key":"1567_CR46","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1126\/science.aaw3242","volume":"367","author":"S Wilmes","year":"2020","unstructured":"Wilmes, S. et al. Mechanism of homodimeric cytokine receptor activation and dysregulation by oncogenic mutations. Science 367, 643\u2013652 (2020).","journal-title":"Science"},{"key":"1567_CR47","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1107\/S0907444910007493","volume":"66","author":"P Emsley","year":"2010","unstructured":"Emsley, P. et al. Features and development of COOT. Acta Crystallogr. D Biol. Crystallogr. 66, 486\u2013501 (2010).","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"1567_CR48","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1107\/S2059798319011471","volume":"75","author":"D Liebschner","year":"2019","unstructured":"Liebschner, D. et al. Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix. Acta Crystallogr. D Biol. Crystallogr. 75, 861\u2013877 (2019).","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"1567_CR49","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1182\/blood-2010-01-265041","volume":"116","author":"JN Kochenderfer","year":"2010","unstructured":"Kochenderfer, J. N. et al. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood 116, 2875\u20132886 (2010).","journal-title":"Blood"},{"key":"1567_CR50","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.cell.2014.03.047","volume":"157","author":"ME Birnbaum","year":"2014","unstructured":"Birnbaum, M. E. et al. Deconstructing the peptide-MHC specificity of T cell recognition. Cell 157, 1073\u20131087 (2014).","journal-title":"Cell"}],"container-title":["Nature Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41587-022-01567-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41587-022-01567-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41587-022-01567-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T09:35:17Z","timestamp":1728639317000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41587-022-01567-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,2]]},"references-count":50,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["1567"],"URL":"https:\/\/doi.org\/10.1038\/s41587-022-01567-w","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.742478214.793598242","asserted-by":"object"}]},"ISSN":["1087-0156","1546-1696"],"issn-type":[{"value":"1087-0156","type":"print"},{"value":"1546-1696","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,2]]},"assertion":[{"value":"16 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.N., X.Y. and K.C.G. are inventors on a patent application (serial no. 63\/187,735, filed 12\u2009May 2021). K.C.G. is a cofounder of 3T Biosciences. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}